Matches in SemOpenAlex for { <https://semopenalex.org/work/W4297995356> ?p ?o ?g. }
Showing items 1 to 85 of
85
with 100 items per page.
- W4297995356 endingPage "S1243" @default.
- W4297995356 startingPage "S1243" @default.
- W4297995356 abstract "Despite optimal treatment, up to 40% of patients with soft-tissue sarcomas (STS) will develop metastatic disease. In this setting, the standard of care is based on palliative chemotherapy with a median survival of only 18 months. Innovative treatments are therefore urgently needed in this setting. Our group has recently shown that STS characterized by the presence of intratumoral tertiary lymphoid structures (TLSs) are particularly sensitive to immune-checkpoint inhibitors (Italiano et al Nature Medicine 2022, In Press). We and others have also shown a strong upregulation of LAG3 in TLS-positive STS which prevent the onset of autoimmunity. Altogether, these findings suggest that simultaneously inhibiting PD1 and LAG3 could lead to a better clinical benefit in inflamed STS. CONGRATS is a multicentric, randomized non-comparative, open-label, two-arm phase 2 trial investigating the efficacy of nivolumab in association with relatlimab in patients with advanced STS with presence of tertiary lymphoid structures (assessed centrally). This study will randomize ∼67 patients with one patient randomized in experimental arm (nivolumab + relatlimab) for one patient randomized in standard arm (nivolumab alone). Eligible patients must have unresectable or metastatic, no standard treatment options available or a contraindication to standard treatment options, and ECOG PS 0–1. Patients with prior exposure to PD1/PDL1 or LAG-3 agonist are excluded. Nivolumab will be administered IV at the dose of 240 mg on days 1 and 15 every 4 weeks. Relatlimab will be administered IV at the dose of 80 mg on days 1 and 15 every 4 weeks. The primary endpoint, assessed independently for each arm, is progression-free rate at 6 months as per RECIST 1.1. Secondary endpoints include adverse events (AEs)/serious AEs, progression-free and overall survivals. Pharmacodynamic and biomarkers will be explored. The first patient received study drug on April 21, 2020. This research is supported by Bristol-Myers Squibb International Corporation. NCT04095208, September 19, 2019. Institut Bergonié, Bordeaux. Bristol-Myers Squibb International Corporation." @default.
- W4297995356 created "2022-10-01" @default.
- W4297995356 creator A5001862184 @default.
- W4297995356 creator A5009725436 @default.
- W4297995356 creator A5012166159 @default.
- W4297995356 creator A5012336500 @default.
- W4297995356 creator A5012605449 @default.
- W4297995356 creator A5019600618 @default.
- W4297995356 creator A5028220670 @default.
- W4297995356 creator A5045509523 @default.
- W4297995356 creator A5048803313 @default.
- W4297995356 creator A5048878548 @default.
- W4297995356 creator A5060934349 @default.
- W4297995356 creator A5064922723 @default.
- W4297995356 creator A5074107335 @default.
- W4297995356 creator A5079233033 @default.
- W4297995356 creator A5084410635 @default.
- W4297995356 date "2022-09-01" @default.
- W4297995356 modified "2023-09-23" @default.
- W4297995356 title "1527TiP CONGRATS-combination of nivolumab plus relatlimab in patients with advanced or metastatic soft-tissue sarcoma: A proof-of-concept randomized phase II study" @default.
- W4297995356 doi "https://doi.org/10.1016/j.annonc.2022.07.1916" @default.
- W4297995356 hasPublicationYear "2022" @default.
- W4297995356 type Work @default.
- W4297995356 citedByCount "0" @default.
- W4297995356 crossrefType "journal-article" @default.
- W4297995356 hasAuthorship W4297995356A5001862184 @default.
- W4297995356 hasAuthorship W4297995356A5009725436 @default.
- W4297995356 hasAuthorship W4297995356A5012166159 @default.
- W4297995356 hasAuthorship W4297995356A5012336500 @default.
- W4297995356 hasAuthorship W4297995356A5012605449 @default.
- W4297995356 hasAuthorship W4297995356A5019600618 @default.
- W4297995356 hasAuthorship W4297995356A5028220670 @default.
- W4297995356 hasAuthorship W4297995356A5045509523 @default.
- W4297995356 hasAuthorship W4297995356A5048803313 @default.
- W4297995356 hasAuthorship W4297995356A5048878548 @default.
- W4297995356 hasAuthorship W4297995356A5060934349 @default.
- W4297995356 hasAuthorship W4297995356A5064922723 @default.
- W4297995356 hasAuthorship W4297995356A5074107335 @default.
- W4297995356 hasAuthorship W4297995356A5079233033 @default.
- W4297995356 hasAuthorship W4297995356A5084410635 @default.
- W4297995356 hasConcept C121608353 @default.
- W4297995356 hasConcept C126322002 @default.
- W4297995356 hasConcept C141071460 @default.
- W4297995356 hasConcept C142724271 @default.
- W4297995356 hasConcept C143998085 @default.
- W4297995356 hasConcept C168563851 @default.
- W4297995356 hasConcept C204787440 @default.
- W4297995356 hasConcept C2776494729 @default.
- W4297995356 hasConcept C2777701055 @default.
- W4297995356 hasConcept C2778256501 @default.
- W4297995356 hasConcept C2778629024 @default.
- W4297995356 hasConcept C2780030458 @default.
- W4297995356 hasConcept C71924100 @default.
- W4297995356 hasConceptScore W4297995356C121608353 @default.
- W4297995356 hasConceptScore W4297995356C126322002 @default.
- W4297995356 hasConceptScore W4297995356C141071460 @default.
- W4297995356 hasConceptScore W4297995356C142724271 @default.
- W4297995356 hasConceptScore W4297995356C143998085 @default.
- W4297995356 hasConceptScore W4297995356C168563851 @default.
- W4297995356 hasConceptScore W4297995356C204787440 @default.
- W4297995356 hasConceptScore W4297995356C2776494729 @default.
- W4297995356 hasConceptScore W4297995356C2777701055 @default.
- W4297995356 hasConceptScore W4297995356C2778256501 @default.
- W4297995356 hasConceptScore W4297995356C2778629024 @default.
- W4297995356 hasConceptScore W4297995356C2780030458 @default.
- W4297995356 hasConceptScore W4297995356C71924100 @default.
- W4297995356 hasLocation W42979953561 @default.
- W4297995356 hasOpenAccess W4297995356 @default.
- W4297995356 hasPrimaryLocation W42979953561 @default.
- W4297995356 hasRelatedWork W1521054398 @default.
- W4297995356 hasRelatedWork W2792729135 @default.
- W4297995356 hasRelatedWork W3036710432 @default.
- W4297995356 hasRelatedWork W3041708748 @default.
- W4297995356 hasRelatedWork W3136487994 @default.
- W4297995356 hasRelatedWork W3206074017 @default.
- W4297995356 hasRelatedWork W3215044659 @default.
- W4297995356 hasRelatedWork W4214687963 @default.
- W4297995356 hasRelatedWork W4226078140 @default.
- W4297995356 hasRelatedWork W4383876223 @default.
- W4297995356 hasVolume "33" @default.
- W4297995356 isParatext "false" @default.
- W4297995356 isRetracted "false" @default.
- W4297995356 workType "article" @default.